{"id":68910,"date":"2026-03-02T19:05:15","date_gmt":"2026-03-02T19:05:15","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=68910"},"modified":"2026-05-21T07:03:44","modified_gmt":"2026-05-21T07:03:44","slug":"melanotan-ii","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/melanotan-ii\/","title":{"rendered":"Melanotan II"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Melanotan II?<\/h3>\n

Melanotan II (MTII)<\/strong> is a synthetic seven-amino-acid cyclic analog of alpha-melanocyte stimulating hormone (\u03b1-MSH). It is a broad melanocortin agonist<\/strong> with activity at MC1R, MC3R, MC4R, and MC5R \u2014 distinguishing it from the more MC4R-selective PT-141<\/a>. In research, MTII is studied for melanogenesis, photoprotection, and broader melanocortin pharmacology. Supplied in 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

What you get with MedsBase:<\/strong> Research-grade lyophilized peptides \u00b7 HPLC \u226599% purity (COA on request) \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide peptide courier \u00b7 1,400+ verified customer reviews<\/a><\/div>\n

\ud83d\udce6 Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days, we reship it.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specification<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS Number<\/strong><\/td>\n121062-08-6<\/td>\n<\/tr>\n
Molecular Formula<\/strong><\/td>\nC50<\/sub>H69<\/sub>N15<\/sub>O9<\/sub><\/td>\n<\/tr>\n
Molecular Weight<\/strong><\/td>\n1024.18 Da<\/td>\n<\/tr>\n
Sequence<\/strong><\/td>\nAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2<\/sub><\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyophilized powder (or as supplied)<\/td>\n<\/tr>\n
Purity<\/strong><\/td>\n\u226599% (HPLC verified, COA on request)<\/td>\n<\/tr>\n
Storage<\/strong><\/td>\nLyophilized: 2\u20138\u00a0\u00b0C (refrigerator) for working stock; \u221220\u00a0\u00b0C for long-term storage of unopened vials. Reconstituted: 2\u20138\u00a0\u00b0C, use within ~30 days. Protect from light. Do not freeze\u2013thaw the reconstituted solution.<\/td>\n<\/tr>\n
Solubility<\/strong><\/td>\nBacteriostatic water (recommended) or sterile water for shorter use windows<\/td>\n<\/tr>\n
Research Use<\/strong><\/td>\nFor laboratory research use only. Not for human or veterinary diagnostic or therapeutic use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is Melanotan II?<\/h2>\n

Melanotan II<\/strong> (often abbreviated MTII<\/strong>) is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (\u03b1-MSH). It was developed in the 1980s at the University of Arizona by Hruby and colleagues as an analog designed to resist enzymatic degradation and cross the blood-brain barrier efficiently \u2014 useful tools for melanocortin-receptor pharmacology research.<\/p>\n

Sequence (cyclic): Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2<\/sub>. Molecular weight approximately 1,024.2\u00a0Da. Unlike PT-141<\/a> (bremelanotide), which was refined from Melanotan II specifically to reduce MC1R activity (minimal tanning effect) while preserving MC4R-mediated research signals, Melanotan II retains broad melanocortin agonism<\/strong> \u2014 activity across MC1R, MC3R, MC4R, and MC5R.<\/p>\n

This pan-receptor profile is the central research characteristic of MTII: it drives melanogenesis (MC1R) alongside appetite suppression (MC4R), arousal-pathway signaling (MC4R shared with PT-141), and broader melanocortin effects. Supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Melanotan II is for laboratory research use only<\/strong> and is not intended for human or veterinary diagnosis or therapy. The US FDA has issued multiple public warnings about unregulated Melanotan II use \u2014 it has never received FDA approval and carries documented safety concerns including atypical nevus development, elevated blood pressure, nausea, and focal hyperpigmentation. For deeper mechanism and research context, see our full Melanotan II research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Broad Melanocortin Agonism<\/h2>\n

Melanotan II’s pharmacology is defined by its activity across multiple melanocortin-receptor subtypes, each producing a distinct research-relevant effect:<\/p>\n